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Abstract 
Rationale: The ability to treat invalidating neurological diseases is impeded by the presence of the blood-brain 
barrier (BBB), which inhibits the transport of most blood-borne substances into the brain parenchyma. 
Targeting the transferrin receptor (TfR) on the surface of brain capillaries has been a popular strategy to give 
a preferential accumulation of drugs or nanomedicines, but several aspects of this targeting strategy remain 
elusive. Here we report that TfR-targeted gold nanoparticles (AuNPs) can accumulate in brain capillaries and 
further transport across the BBB to enter the brain parenchyma.  
Methods: We characterized our targeting strategy both in vitro using primary models of the BBB and in vivo 
using quantitative measurements of gold accumulation by inductively-coupled plasma-mass spectrometry 
together with morphological assessments using light microscopy after silver enhancement and transmission 
electron microscopy with energy-dispersive X-ray spectroscopy. 
Results: We find that the uptake capacity is significantly modulated by the affinity and valency of the 
AuNP-conjugated antibodies. Specifically, antibodies with high and low affinities mediate a low and intermediate 
uptake of AuNPs into the brain, respectively, whereas a monovalent (bi-specific) antibody improves the uptake 
capacity remarkably.  
Conclusion: Our findings indicate that monovalent ligands may be beneficial for obtaining transcytosis of 
TfR-targeted nanomedicines across the BBB, which is relevant for future design of nanomedicines for brain 
drug delivery. 
Key words: Brain drug delivery; gold nanoparticle; transferrin receptor; targeting; affinity 
Introduction 
Despite decades of technological advances, 
delivery of therapeutically active compounds to the 
brain remains a critical challenge for the treatment of 
neurological disorders [1, 2]. The low accumulation of 
drugs in the brain is due to the presence of the 
blood-brain barrier (BBB), which restricts passage of 
most compounds into the brain [3]. While the BBB is a 
major challenge for drug transport into the brain, it 
contains many receptor and transport proteins that 
are responsible for nutrient transport into the brain 
and depict potential targets for brain drug delivery 
technologies [4, 5]. Among the most exploited target 
proteins on the luminal membrane of the BBB, the 
transferrin receptor (TfR) is under normophysio-
logical conditions responsible for binding to and 
endocytosing iron-transferrin (Tf) complexes for 
subsequent iron transport into the brain parenchyma 
[1, 6, 7]. The intracellular sorting mechanism of the 
TfR in brain capillary endothelial cells (BCECs) is 
somewhat disputed, but recent evidence indicates 
that the receptor protein is incapable of transcytosis 
through the BCEC to the abluminal membrane and 
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brain parenchyma [7-10]. Instead, iron is dissociated 
during endosomal acidification and in a multistep 
process pumped into the brain parenchyma 
independent of TfR and Tf transport [7-10]. Thus, this 
model does not suggest the TfR to be a relevant target 
for transport across the BCEC into the brain [1, 6]. 
 While there has been a broad acceptance of the 
abovementioned role of TfR in physiological iron 
transport into the brain without transcellular 
transport of the receptor itself, this role has been 
continuously challenged by evidence from the brain 
drug delivery field [1, 6]. For example, antibody 
constructs efficiently transcytose through the BBB if 
the binding site of the antibody construct is modified 
to reduce the overall affinity towards the TfR [11-16]. 
In addition to the affinity, others have suggested that 
the valency of the antibody construct against the TfR 
is critical for antibody transport across the BBB 
[17-21]. With respect to nanomedicines, the total 
ligand avidity on nanoparticles is also important for 
transport into the brain [22, 23], whereas the impact of 
nanoparticle ligand affinity towards the TfR is less 
well understood [24]. Importantly, despite critique 
raised towards the binding kinetics of a nanoparticle 
to the brain endothelial cell and the ability of 
nanoparticles to transport into the brain [17], whole 
TfR-targeted gold nanoparticles (AuNPs) were 
observed in the brain parenchyma after intravenous 
administration, suggestive of a functional transport 
mechanism of this nanoparticle across the BBB 
mediated by the TfR [22, 23]. 
 The objective of the present study was to 
investigate the impact of ligand binding mode for 
nanoparticle transport into the brain. Based on the 
currently available literature, we expected that 
modifying the binding affinity or valency of the 
antibodies targeting the TfR would reduce the brain 
uptake of the nanoparticle because the strength of the 
initial interaction between the nanoparticle and the 
BCEC would be too low to initiate proper endocytosis 
of the nanoparticle [1, 6]. To study this hypothesis, we 
decided to examine AuNPs, as they have 
multifunctionality with respect to the downstream 
analysis of brain uptake [23]. Concerning the targeting 
ligands, we gained access to the antibodies developed 
by Yu et al. [16], which allowed for evaluation of both 
the difference in affinity (anti-TfRA versus anti-TfRD) 
and mono- versus bivalency (anti-TfRA/BACE1 
versus anti-TfRA) of the TfR-targeting antibody in 
relation to the subsequent brain uptake of AuNPs. In 
addition, novel lipoic acid-terminated polyethylene 
glycol 5000 (PEG5000-LA) constructs were synthesized 
for polymer surface coating and antibody 
functionalization of the AuNPs. 
 We report here that lowering the affinity of the 
TfR-targeting antibody on the AuNP surface 
improved the brain uptake modestly but using a 
monovalent binding antibody increased the brain 
uptake markedly. This was shown using the 
bi-specific antibody, anti-TfRA/BACE1. While BACE1 
targeting may have a therapeutic potential in relation 
to the treatment of Alzheimer’s disease [25], we could 
not prove this effect when the anti-TfRA/BACE1 
antibody was conjugated to the AuNPs. We quantif-
ied the differences in transport both in vitro and in 
vivo after brain capillary depletion and subsequent 
inductively-coupled plasma-mass spectrometry 
(ICP-MS) assessment, and we detected AuNPs in the 
brain parenchyma using both light microscopy and 
transmission electron microscopy (TEM) with 
energy-dispersive X-ray spectroscopy (EDS).  
Results 
Production of TfR-targeted AuNPs with 
varying affinities and valencies 
To study the impact of antibody affinity and 
valency on the brain uptake of nanoparticles, we 
decided to use AuNPs as our model system, because 
these nanoparticles allow ample detection with 
methodologies including ICP-MS, light microscopy 
after silver enhancement, and TEM with EDS. 
Uniform AuNPs were produced by a sodium acrylate 
reduction of a gold salt in solution, done sequentially 
to obtain a final size of the AuNP core of 52.8 ± 0.7 nm 
with low polydispersity (Table 1). The AuNPs were 
subsequently surface-coated with a layer of 
PEG5000-LA (for schematic, please refer to Figure 1), 
further increasing the hydrodynamic diameter of the 
AuNP as determined by dynamic light scattering 
(DLS; Table 1). Inclusion of a small fraction of 1% 
maleimide-functionalized PEG5000 (Mal-PEG5000-LA) 
allowed for conjugation of thiolated anti-TfR 
antibodies via standard Michael-type addition. The 
thiolation of the different antibodies was optimized 
through a screening process to tune the number of 
reactive thiols group to approximately one per 
antibody (Figure S1). All antibodies were tested for 
their reactivity towards the mouse TfR using surface 
plasmon resonance prior to conjugation to the AuNPs 
ensuring the desired affinity of the individual 
antibodies (Table 2 and Figure S2). After the 
conjugation reaction between the antibodies and 
AuNPs, all formulations had comparable size 
distributions and number of antibodies present on the 
AuNP surface, as directly measured by dot blot 
(Table 1). Using TEM with EDS, it was possible to 
validate the homogenous appearance and the 
presence of gold in all formulations (Figure 2). 
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Table 1. DLS, ζ-potential, UVmax, and polydispersity index of the 
AuNPs 
Group Hydrodynamic 
diameter (nm) 
ζ-potential 
(mV) 
UVmax 
(nm) 
PDI Antibodies 
per AuNP 
AuNPs 1st seed 35.7 ± 0.2 -32.8 ± 0.8 524 0.016 - 
AuNPs 2nd seed 52.8 ± 0.7 -31.7 ± 5.9 534 0.082 - 
mPEG AuNPs 92.6 ± 1.5 -27.2 ± 3.4 534 0.079 - 
mPEG AuNPs + 
maleimide 
82.0 ± 1.6 -40.4 ± 1.6 536 0.206 - 
Isotype IgG AuNPs 75.1 ± 0.6 -24.9 ± 0.7 536 0.249 8.8 
Anti-TfRA AuNPs 75.2 ± 1.6 -21.4 ± 1.0 536 0.217 6.5 
Anti-TfRD AuNPs 74.8 ± 1.1 -16.7 ± 1.4 536 0.245 8.6 
Anti-TfRA/BACE1 
AuNPs 
77.0 ± 0.3 -24.1 ± 1.5 536 0.250 7.5 
 
AuNP uptake and transport across the 
blood-brain barrier is increased by 
TfR-targeting in vitro 
The AuNP formulations were administrated to 
an in vitro model of the BBB based on freshly isolated 
mouse BCECs grown in co-culture with primary 
mouse astrocytes (Figure 3A). The transendothelial 
electrical resistance (TEER) of the barriers was high 
(~150 Ω cm2), indicating a tight model of the BBB to 
study the AuNP transport (Figure 3B) [26]. 
Importantly, there was no measurable reduction in 
the barrier integrity during the experiment, as 
indicated by the TEER being maintained at a high 
level (Figure 3B). The mouse BCECs of the in vitro 
models expressed relevant tight junction (TJ) proteins 
including CD31, ZO-1, occludin, and claudin-5 
together with the TfR (Figure 3C and Figure S3). TfR 
expression could also be confirmed in BCEC lysates 
by Western blotting (Figure S4). After incubation of 
the BCECs with the different AuNP formulations, 
there was an increased uptake of AuNPs into the 
BCECs as a function of TfR targeting compared to the 
mPEG and isotype IgG control formulations (Figure 
3D, p < 0.01). In general, there was a high baseline 
level of uptake, which may be due to the high density 
 
 
Figure 1. Overview of experimental setup. (A) Schematic representation of the synthesis strategy resulting in TfR-targeted AuNPs. (B) Illustration of the different groups 
compared in subsequent experiments. 
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of the AuNPs, but overall, this level of uptake was 
doubled by targeting of the TfR (Figure 3D). The 
transport of AuNPs to the opposite (brain) side of the 
Transwell culture system was also measured, 
showing that the transport capacity, especially of 
anti-TfRA/BACE1 monovalent variant AuNPs, was 
increased (Figure 3E). This yielded the highest levels 
of transendothelial transport compared to the mPEG 
and isotype IgG controls (p < 0.05), although the 
absolute numbers of AuNPs being transported in this 
model were disappearingly small (Figure 3E). One 
reason for the low numbers of AuNP being detected 
in the bottom chamber of the culture system could be 
the possibility that the transcytosed AuNPs interacted 
with the polycarbonate membrane of the Transwell 
inserts (Figure 3A). In addition, the static conditions 
of the Transwell setup do not account for the effect of 
blood flow, and thus, the impact of targeting on both 
uptake and transport across the BBB may have been 
underestimated in the in vitro system. 
 
Table 2. Biacore analysis of anti-TfR antibodies against 
recombinant mouse TfR 
Group Host Reactivity Dissociation constant (nM) 
Isotype IgG  Human - 3200 
Anti-TfRA  Human Mouse  21 
Anti-TfRD  Human Mouse 149 
Anti-TfRA/BACE1  Human Mouse 22 
RI7217 Rat Mouse 6 
OX26 Mouse Rat 1600 
 
Brain accumulation of AuNPs is improved with 
lower affinity and monovalency of the antibody  
To study the brain targeting abilities of the 
different AuNP formulations, they were injected via 
the lateral tail vein into mice and allowed to circulate 
for 8 h. Lethargy has previously been observed after 
injection of these humanized anti-TfR antibodies [12, 
27], but we saw no signs of this adverse effect, 
possibly due to the low overall protein concentration 
of the injected AuNP solution. First, the biodistri-
bution profiles of the AuNP formulations were 
determined by measuring gold content in resected 
tissue samples from a range of peripheral organs and 
the brain using ICP-MS (Figure 4A). The different 
AuNP formulations primarily accumulated in the 
liver and the spleen, while approximately 3–7 %ID/g 
remained in the plasma after 8 h. The low plasma 
concentration may be a result of the high density of 
AuNPs, which would allow for pelleting the AuNPs 
together with red blood cells during plasma isolation. 
Particularly, attaching an antibody on the surface of 
the AuNP (regardless of its targeting qualities) 
seemed to increase the liver uptake of the 
formulations compared to a non-functionalized 
(mPEG) control. This was also observed in the spleen, 
although in this organ the TfR-targeted AuNP 
formulations with the highest affinity of the 
conjugated antibody (anti-TfRA and anti-TfRA/ 
BACE1) seemed to accumulate several-fold more 
 
Figure 2. TEM evaluation of AuNPs. TEM with EDS was performed to characterize the homogeneity, size, and composition of the AuNPs. All groups of AuNPs presented 
with a homogenous shape (A-E) and size distribution (F-J). A minimum of 250 AuNPs were analyzed in each group to produce the size distribution diagrams. In addition, using 
EDS, the presence of gold was validated in all groups of AuNPs (K-O). Scale bars depict 100 nm. 
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compared to the controls (Figure 4A). TEM analysis 
confirmed this large accumulation, which was readily 
observable both in liver (Figure 4B-C) and spleen 
(Figure 4D-E) tissue samples. Interestingly, we did 
not observe any AuNP uptake into hepatocytes 
despite their prominent TfR expression. We found 
them only to be phagocytosed by resident Kupffer 
cells (Figure 4B-C). No significant differences were 
observed with respect to the uptake in other 
peripheral tissues including the kidney, heart and 
lungs, whereas the general brain accumulation varied 
correlating with the binding modus of the 
TfR-targeting antibody (Figure 4A). Here, the AuNPs 
functionalized with the low-affinity anti-TfRD variant 
antibodies accumulated more compared to their 
high-affinity anti-TfRA counterparts (~1.4-fold 
increase), although the difference did not reach 
statistical significance (Figure 4A). However, the 
AuNPs functionalized with the anti-TfRA/BACE1 
monovalent variant antibody seemed to outperform 
both AuNP formulations functionalized with bivalent 
antibodies (~4.5-fold and 3.2-fold increase compared 
to the anti-TfRA and anti-TfRD variants, respectively) 
with respect to general brain accumulation (p < 0.001 
against anti-TfRA, p < 0.05 against anti-TfRD, Figure 
4A). 
 
 
Figure 3. Determination of AuNP transport across the BBB in vitro. (A) Schematic representation of the in vitro model system of the BBB derived from primary 
mouse BCECs and astrocytes and exposed to BBB induction factors. (B) The in vitro models had a high electrical resistance across the BCEC layer, which did not change over 
the course of the experiment (n = 24). (C) The in vitro models expressed the TfR together with several TJ-related proteins, including CD31, ZO-1, occludin and claudin-5. XZ 
planes are presented underneath each image. Single channel images can be viewed in Figure S3. Scale bar depicts 10 µm. (D) BCEC uptake of AuNPs after five hours in the in 
vitro models. Increased uptake was observed for the TfR-targeted AuNPs compared to the isotype IgG and mPEG controls (p < 0.01, n = 4 – 5, Kruskal-Wallis test with Dunn’s 
multiple comparisons post hoc test). (E) Transport of AuNPs across the in vitro model of the BBB. Only AuNPs functionalized with the monovalent antibody, anti-TfRA/BACE1, 
were transported to a higher extent across the BCECs with statistical significance (p < 0.05, n = 4 – 5, Kruskal-Wallis test with Dunn’s multiple comparisons post hoc test). Data 
are presented as mean ± SEM (n = 4 – 5) with * p < 0.05 and ** p < 0.01. %AD: percentage of administrated dose; BCECs: brain capillary endothelial cells; TEER: transendothelial 
electrical resistance; TfR: Transferrin receptor; ZO-1: Zonula occludens 1. 
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Figure 4. Biodistribution analysis of AuNPs after intravenous injection. 
(A) AuNPs accumulated to a high extent in both the liver and the spleen, although in 
the liver the accumulation seemed to scale with the presence of antibodies on the 
surface of the AuNPs, whereas for the spleen, the accumulation tended to follow the 
TfR-targeting abilities of the functionalized AuNPs. Large accumulation in the liver 
(B-C) and spleen (D-E) could be detected using TEM. (B-C) In the liver, AuNPs 
were seen in Kupffer cells situated in the sinusoidal lumen near the endothelial cell 
layer and hepatocytes. (D-E) In the spleen, AuNPs were also seen in macrophages 
with the AuNPs clearly accumulating in vesicular structures. Scale bars depict 200 nm. 
In other peripheral organs, the general accumulation of the AuNPs was low with no 
differences between the individual groups. The brain accumulation of AuNPs was 
improved for the targeted variants compared to the non-targeted variants of AuNPs 
(statistical significance was found for all TfR-targeted AuNPs compared to both 
controls, except for anti-TfRA versus isotype IgG (p > 0.05), but not presented in the 
figure for the sake of a clear overview). The highest brain accumulation was seen for 
the monovalent anti-TfRA/BACE1 group, which outperformed both the high and 
low-affinity variants (p < 0.001 and p < 0.05, respectively). Data are presented as 
mean ± SEM (n = 7–8) with * p < 0.05 and *** p < 0.001. ec: endothelial cell; hc: 
hepatocyte; kc: Kupffer cell; mp: macrophage; sl: sinusoidal lumen; vs: vesicular 
structure; %ID/g: Percentage of injected dose per gram. 
 
TfR-targeting with monovalent antibodies 
significantly improves the transport of AuNPs 
into the brain parenchyma 
Given the interesting differences in brain 
accumulation observed between the different AuNP 
formulations, we chose to investigate further the type 
of uptake, i.e., whether the increase in brain gold 
content could be attributed only to an increased brain 
capillary uptake, or whether it also translated into a 
measurable transport of AuNPs into the brain 
parenchyma. Therefore, brain capillary depletion was 
performed to separate the capillary and parenchymal 
fractions, and these fractions were subsequently 
analyzed for their gold content (Figure 5A-C; whole 
brain homogenate data from Figure 4A re-included as 
Figure 5A for comparison to the capillary and 
parenchymal fractions). The purity of each fraction 
was confirmed by measuring the enzyme activity of 
γ-glutamyl transferase (Figure S5). As expected, the 
AuNP uptake into the brain capillaries was high for 
the TfR-targeted variants (Figure 5B) compared to 
what was observed in the whole brain homogenates 
(Figure 5A) and parenchymal fractions (Figure 5C), 
suggestive of up-concentration at this anatomical site. 
This also correlated well with the brain capillaries 
being the entry point to the brain for compounds 
injected into the systemic circulation. Interestingly, for 
the capillary fraction, the accumulation of AuNPs was 
higher for the low-affinity anti-TfRD variant compared 
to the high-affinity anti-TfRA variant (Figure 5B), but 
again the difference did not reach statistical 
significance (p > 0.05). In the parenchymal fraction, 
the difference between the high-affinity anti-TfRA and 
the low-affinity anti-TfRD variants was statistically 
significant (Figure 5C, p < 0.05), suggestive of 
improved trans-BBB transport. However, these were 
both inferior to the monovalent anti-TfRA/BACE1 
variant (Figure 5C, p < 0.001 against anti-TfRA, p < 
0.05 against anti-TfRD for both the capillary and 
parenchymal fractions). In the capillary fraction, this 
increased level of AuNP accumulation amounted to 
more than 1.1 %ID/g, whereas this figure was 0.23 
%ID/g in the parenchymal fraction (Figure 5B-C). 
This indicated that having a monovalent TfR antibody 
on the AuNP surface was favorable for subsequent 
transport across the BBB after intravenous 
administration. Since the monovalent anti-TfRA/ 
BACE1 variant AuNPs seemed to accumulate to a 
high degree in the brain parenchyma, we measured 
the total brain content of β-amyloid after 30 h to 
evaluate if this level of accumulation allowed for any 
therapeutic effects of the anti-BACE1 arm. We could 
not, however, detect any change in the brain 
β-amyloid load even after doubling the initial 
anti-TfRA/BACE1 AuNP dose used for the 
quantitative transport studies (Figure S6). 
AuNPs locate to multiple structures inside the 
brain parenchyma 
While the brain capillary depletion technique is a 
suitable tool to indicate the transport of compounds 
into the parenchymal compartment of the brain (i.e., 
transported across the BBB), it lacks the robustness of 
being a standalone analysis. Therefore, we adopted 
the morphological approach described by Wiley et al. 
[23] and performed silver enhancement on brain 
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sections from mice having received the different 
AuNP formulations for subsequent light microscopy 
(Figure 6). Using this technique, it was apparent that 
(like when measured using brain capillary depletion) 
most AuNPs observed in the brain sections were in 
vessel-like structures, suggestive of capillary uptake 
and concentration (Figure 6). In mice receiving either 
the low-affinity anti-TfRD or the monovalent anti- 
TfRA/BACE1 variants, AuNPs not associated with 
vessel-like structures could be observed (Figure 
6D-E), which indicated that a smaller fraction of these 
AuNPs had transcytosed into the brain parenchyma. 
This observation was seldom in mice receiving the 
high-affinity anti-TfRA variant AuNPs (Figure 6C), 
and not detected in mice receiving mPEG or isotype 
IgG-functionalized AuNPs (Figure 6A-B). Capillary 
accumulation could, however, be observed to a minor 
extent for the isotype IgG AuNPs (Figure 6A). 
Immunohistochemical staining against the human Fc 
region of the AuNP-conjugated antibodies did not 
reveal any signal indicative of antibody accumulation 
along the brain capillaries, which was likely due to the 
low level of accumulation combined with the small 
number of antibodies per AuNP (data not shown). 
To further substantiate our claim that a fraction 
of AuNPs had transcytosed into the brain 
parenchyma, we performed TEM on brains resected 
from mice having received the different AuNP 
formulations (Figure 7). The TEM analysis also 
allowed us to measure the presence of gold by way of 
EDS (in addition to the direct visualization), which 
could validate the findings as true AuNPs and not just 
salt precipitates or other artifacts. Similar to the 
results of the brain capillary depletion and silver 
enhancement techniques, the TEM analysis showed 
the presence of TfR-targeted AuNPs in the capillaries 
of the brain (Figure 7C-E), whereas no AuNPs could 
be detected in the brains of mice receiving either 
mPEG or isotype IgG-functionalized AuNPs (Figure 
7A-B). All AuNPs observed in the brain capillaries 
were associated with intracellular vesicular struct-
ures, which correlated with the TfR being an 
endocytosing receptor (Figure 7C-E and Figure S7). 
AuNPs were generally located to the larger capillary 
branches, whereas AuNP uptake in the smallest 
capillaries was seldom (Figure S8). Interestingly, we 
also observed a smaller fraction of TfR-targeted 
AuNPs on the abluminal side of the BCECs (Figure 
7H-J), which indicated full transcytosis of the AuNP, 
especially prominent for the monovalent anti-TfRA/ 
BACE1 variant (Figure 7J and Figure S9). For 
example, AuNP could be observed directly below the 
 
Figure 5. Accumulation of AuNPs in different brain fractions after capillary depletion. (A) In whole brain homogenates, there was a clear distinction between the 
different TfR-targeted variants with respect to accumulation of AuNPs (whole brain homogenate data from Figure 3A re-included as Figure 4A for comparison to the capillary 
and parenchymal fractions). (B) The TfR-targeted AuNPs accumulated in the capillary fraction with 0.2, 0.5, and 1.1 %ID/g for anti-TfRA, anti-TfRD (p > 0.05 against anti-TfRA), 
and anti-TfRA/BACE1 (p < 0.001 against anti-TfRA, p < 0.05 against anti-TfRD, respectively). (C) In the brain parenchyma, gold could also be detected, indicative of AuNP 
transport across the BBB. More accumulation was seen for the low-affinity anti-TfRD compared to the high-affinity anti-TfRA variant AuNPs (p < 0.05). Anti-TfRA/BACE1 AuNPs 
were superior to the other TfR-targeted variant AuNPs with a mean parenchymal accumulation of 0.23 %ID/g compared to 0.04 and 0.08 %ID/g for anti-TfRA and anti-TfRD, 
respectively (p < 0.001 against anti-TfRA, p < 0.05 against anti-TfRD). Statistical significance was proven for all TfR-targeted AuNPs compared to both controls in brain capillaries 
and parenchyma after capillary depletion, but not presented in the figure for the sake of a clear overview. Data are presented as mean ± SEM (n = 7–8, Kruskal-Wallis test with 
Dunn’s multiple comparisons post hoc test) with * p < 0.05 and *** p < 0.001. %ID/g: percentage of injected dose per gram. 
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endothelial basement membrane, in pericytes, and 
inside neural axons/processes (Figure 7 and Figure 
S9). All AuNPs present inside brain capillaries and in 
any region of the brain parenchyma had their gold 
content validated by EDS (representative spectra for 
transcytosed AuNPs shown in Figure 7K-M). 
Discussion 
The use of nanoparticles for drug delivery to the 
brain has been scrutinized in several studies, 
however, often only with minor characterization of 
their mobility at the BBB, as opposed to transport of 
 
Figure 6. Detection of AuNPs in brain tissue after silver enhancement. (A) In mice treated with mPEG AuNPs, no silver grains representing AuNPs could be observed 
in the brain tissue, (B) whereas some silver grains were observed in capillary structures of mice treated with isotype IgG AuNPs. For all TfR-targeted variants, silver grains 
representing AuNPs presented as a dotted lining of the capillary structures, indicative of accumulation at this anatomical location (C-E). (C) In mice treated with anti-TfRA 
AuNPs, there was only little intraparenchymal staining, (D) whereas examples of this could be observed in mice treated with anti-TfRD AuNPs (arrows). (E) In mice treated with 
anti-TfRA/BACE1 AuNPs, detection of intraparenchymal staining (indicative of AuNP transcytosis) was more apparent (arrows). Quantification was not performed based on the 
silver enhancement technique. Scale bar depicts 25 µm. 
 
Figure 7. TEM detection of AuNPs in brain tissue. Direct visualization of AuNPs in the brain capillaries and parenchyma of treated mice was performed using TEM (n = 
2–4). (A-B) No AuNPs could be detected in brain capillaries of mice in the mPEG or isotype IgG groups, whereas the TfR-targeted AuNPs could easily be found at this location 
(C-E). All AuNPs detected in capillaries were confined to vesicular structures, suggesting receptor-mediated endocytosis as the uptake mechanism. (F-G) No AuNPs could be 
detected in brain parenchyma of mice in the mPEG or isotype IgG groups. (H-J) AuNPs were observed beyond the BBB or in the brain parenchyma of mice treated with all 
TfR-targeted variants but were most easily detected in the anti-TfRA/BACE1 group (J). All AuNPs detected in the brain parenchyma were analyzed using EDS to validate the 
presence of gold in these electron-dense points (K-M). Scale bars depict 200 nm. bp: brain parenchyma; bm: basement membrane; cl: capillary lumen; ec: endothelial cell; np: 
neural process; pc: pericyte; tj: tight junction; vs: vesicular structure. 
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their encapsulated cargo [1, 6]. To provide more 
knowledge on this issue, we studied AuNPs as they 
are stable nanoparticles, their synthesis is easy to 
control, and they allow for in situ localization using 
several analysis techniques [28]. The AuNPs were 
previously used for various brain drug delivery 
purposes in earlier studies, showing transport 
through the BBB as a function of both targeting 
moiety and the diameter of the nanoparticle complex 
[22, 23, 29-31]. They were also targeted to the TfR on 
multiple occasions, hence revealing the potential of 
transport across the BBB, although with varying 
efficiency [22, 23, 32, 33].  
 In this present study, we investigated the 
transport of AuNPs across the BBB in vitro and in 
vivo both as a function of TfR-targeting and of the 
binding modus between the anti-TfR antibody and 
the TfRs expressed on the BCEC surface. Using the 
antibodies developed by Genentech (anti-TfRA, 
anti-TfRD, and anti-TfRA/BACE1), we demonstrate 
both a modest impact of affinity and a marked impact 
of valency on the absolute transport of AuNPs into the 
brain. As expected, we found that TfR-targeting 
increases the uptake of AuNPs into the brain both in 
vitro and in vivo as compared to non-functionalized 
(mPEG) and isotype IgG-functionalized AuNPs. This 
observation is well-described and shows that under 
normophysiological conditions, the use of active 
targeting is required for brain accumulation of any 
drugs or drug delivery vehicles to occur [33, 34]. 
Whether active targeting is required in the case of 
manifest neurological disease with possible loss of 
BBB integrity is widely discussed [35-38]. Recent 
studies show that for some of the high-incidence, 
neurodegenerative disorders, the loss of BBB integrity 
is negligible for transport of antibody-based drugs 
(150 kDa) [39-45], and hence, will be irrelevant for 
brain drug delivery using larger nanomedicines like 
AuNPs. 
The increased brain accumulation for TfR- 
targeted AuNPs also correlated to the binding modus 
of the surface-bound antibody. Surprisingly, we 
observed that the low-affinity antibodies allowed for 
increased accumulation in the brain capillaries 
compared to those having a high-affinity. This 
observation did not necessarily follow the expectation 
that high-affinity would always lead to a higher level 
of accumulation in the brain capillaries, and it was 
possibly affected by the time point of analysis (8 h 
post injection). We have recently found in rats that 
targeting TfRs with high-affinity antibodies on 
liposomes leads to high capillary accumulation after 1 
h, but that this difference compared to controls was 
lost over the following 24 h [46]. Hence, what we 
measure after 8 h in the present study may not 
encompass the acute increase in accumulation in the 
first hour after injection of the AuNPs. Supporting 
this observation, the immediate interaction, uptake, 
and transcytosis of the AuNPs takes place during the 
initial 30 min post injection, as described by Cabezón 
et al. [33], which may indicate that the time point for 
analysis used in this study is more relevant for 
studying BBB transport and parenchymal 
accumulation, instead of the attachment and uptake 
processes at the luminal surface of the BCEC [33]. We 
also find that the dissociation constant of the 
low-affinity antibody remains within the nanomolar 
range (KD = 149 nM), and accordingly, maintains 
significant binding potential. Thus, lowering the 
affinity of the antibodies denotes a potential strategy 
to make modest increases in the AuNP uptake into the 
brain. Others found that a high-affinity anti-TfR 
antibody increased liposome transport across the BBB 
in vitro compared to an antibody with lower affinity 
[24]. However, the ‘low’ affinity antibody (clone 
RI7217) used in that study has a dissociation constant 
in the low nanomolar range (KD = 6 nM, see Figure 
S2), yielding a 25-fold higher affinity than the 
low-affinity anti-TfRD variant used in this present 
study [16, 24]. 
While lowering the affinity could positively 
impact the transport of AuNPs across the BBB, our 
data points towards a much larger impact on the 
transport process imposed by the monovalency of the 
bi-specific antibody, anti-TfRA/BACE1. Using this 
antibody as a ligand, we observed a more than 
three-fold increase in the brain parenchymal uptake of 
AuNPs compared to the low-affinity anti-TfRD 
variant. This observation falls in line with prior 
findings regarding single antibody constructs 
engineered to be either mono- or bivalent [19, 21]. In 
the latter studies, injection of bivalent TfR-targeted 
antibody constructs (brain shuttles) led to only minor 
transport into the brain parenchyma, and more 
critically, resulted in a loss of TfR expression on the 
luminal surface of the BCECs [19]. The loss of TfRs 
after treatment with bivalent antibody constructs has 
been known for a long time, and points to the fact that 
bivalent interactions between the ligand and multiple 
receptors result in a distorted internalization and 
sorting process not favoring transendothelial 
transport into the brain parenchyma [17, 47, 48]. 
Conversely, engineering the brain shuttles to become 
monovalent allowed for increased transport into the 
brain without loss of TfR expression on the BCEC 
surface [19]. Monovalency was also shown to be 
important for brain uptake of antibody-based PET 
tracers for β-amyloid plaque imaging [18, 20]. We 
found no differences between the dissociation 
constants of the high-affinity and monovalent 
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variants of antibodies when analyzed using surface 
plasmon resonance (KD = 21 nM versus 22 nM, 
respectively, Figure S2), because the setup did not 
allow for one antibody molecule interacting with 
several TfRs (anti-TfRA/BACE1 was previously found 
to have an IC50 = 18 nM [12]). In addition, the level of 
functionalization of antibodies per AuNP was 
comparable across the groups. These aspects are 
important because they allow for interpreting the 
difference in brain uptake between the anti-TfRA and 
anti-TfRA/BACE1 variant AuNPs as being caused by 
the difference in the valency of the antibodies. Others 
showed that the avidity of AuNPs is important for 
BBB transport of AuNPs and liposomes [23, 34]. This 
applied when using endogenous Tf as a ligand, but 
when performing the studies using comparable levels 
of functionalization with bivalent antibodies, most of 
the transport capabilities were lost [22, 23]. Our 
results underscore this concept, since we found 
improved uptake using a monovalent antibody and a 
low level of functionalization (< 10 antibodies per 
AuNP). This reduces the probability of interacting 
with multiple TfRs simultaneously, which was 
previously suggested to reduce the relevance of 
targeted nanoparticles for brain drug delivery [17]. 
We cannot, however, rule out the possibility that the 
higher capillary accumulation resulted in an 
unspecific mechanism of release of the AuNPs to 
either the blood or the brain side of the BBB, hereby 
explaining why the transport into the brain 
parenchyma scales with the initial capillary 
accumulation. In addition, we did not observe any 
therapeutic effects of the anti-TfRA/BACE1 antibody 
as assessed by measuring the β-amyloid load in the 
treated brains, as was shown for bi-specific antibody 
constructs in several studies [16, 49]. This was likely 
due to the low amount of total protein injected but 
could also be due to the immobilization of antibodies 
on AuNPs. This is known to suppress the ability of the 
antibody to initiate antibody-dependent cellular 
cytotoxicity because the Fc domains are inaccessible 
for interaction with immune cells [50]. 
Transport of TfR-targeted nanoparticles across 
the BBB is a controversial subject, since the known 
sorting pathway of the TfR does not include 
transcytosis through the endothelial layer, and 
because nanoparticles like the AuNPs used in the 
present study are of a size thousand-fold larger than 
that of the Tf protein [1, 7, 9]. The ability of 
TfR-targeted nanoparticles to pass the BBB and 
accumulate in the brain parenchyma has been claimed 
for many years [1, 6, 34, 51-56], although only a few 
studies have investigated the localization of the 
nanoparticle itself, and not just the cargo [22, 23, 32, 
33, 57]. We demonstrate the presence of AuNPs in the 
brain parenchyma based on quantitative analysis of 
the parenchymal fraction of a brain homogenate after 
capillary depletion. This technique is widely used to 
estimate any transport of substances across the BBB, 
and its robustness has been validated in several 
studies [1, 46, 58, 59]. To ensure the purity of the 
resulting fractions, we quantified the potential 
spillover by measuring the enzyme activity of 
γ-glutamyl transferase in the capillary and 
parenchymal fractions. In the parenchymal fractions, 
there was only very little activity of the enzyme, 
which is suggestive of a capillary depletion with good 
separation and high purity. To substantiate our 
claims, we increased the AuNP size in situ using the 
silver enhancement technique to validate the presence 
of AuNPs in the brain tissue via light microscopy. The 
chemistry of this technique is well-known and it has 
been used quantitatively for studies of AuNP 
transport into the brain [22, 23, 60, 61]. We found that 
most silver-enhanced AuNPs located in vessel-like 
structures with few examples of transcytosis into the 
brain parenchyma, especially for the anti-TfRA/ 
BACE1 variant AuNP group. We also visualized the 
AuNPs directly in the brain cortex using TEM, which 
showed that AuNPs could indeed be found in the 
brain parenchymal structures distant from capillaries, 
although, as depicted by the ICP-MS data, the 
absolute numbers were low. AuNPs were found 
beneath the endothelial basement membrane of the 
BBB, in pericytes, and in neural axons/processes. 
Whether nanoparticles and other large molecules are 
mobile in the brain extracellular space after 
transcytosis from the systemic circulation is still a 
matter of dispute, and their diffusion properties 
remain poorly understood [62]. Some suggest the 
width of the brain extracellular space to be maximum 
64 nm [63], whereas others claim that nanoparticles of 
100 nm can move in this compartment [64, 65]. The 
AuNPs used here were > 70 nm, which is above the 
limit previously described [63], and although our 
TEM approach was not quantitative, we did not 
observe any AuNPs in the extracellular space of the 
brain, but instead they were mostly localized in neural 
processes. We speculate that the distribution of the 
minor fraction of AuNPs that had traversed the BBB 
to the neurons was facilitated by the astrocytes, as has 
previously been hypothesized, rather than diffusing 
freely in the brain extracellular space [66]. 
In conclusion, the findings presented in this 
study indicate that using monovalent antibodies 
targeting the TfR expressed by BCECs increases the 
uptake of AuNPs into the brain parenchyma, whereas 
lowering the affinity may have a modest impact. 
Whether these findings will translate into relevance 
for other types of nanoparticles goes beyond this 
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study, and future studies should seek to validate that 
an increase in absolute uptake of any type of 
nanoparticle formulation also leads to increased 
therapeutic efficacy inside the brain parenchyma. 
Although the number of AuNPs transported to the 
brain parenchyma relative to the injected dose 
remains low, our study shows that shifting from a 
bivalent to a monovalent binding modus results in a 
several-fold increase in brain uptake. The 
improvement of the targeting strategy presented here 
may thus provide a significant contribution to a future 
design of a highly efficient nanoparticle formulation 
for brain drug delivery of otherwise BBB 
impermeable large molecules. 
Methods 
Materials 
All chemicals were purchased from 
Sigma-Aldrich Inc. (Brøndby, Denmark) unless 
otherwise stated. Rabbit anti-claudin 5 (Cat. No. 
SAB4502981) and γ-Glutamyl Transferase (GGT) 
Activity Colorimetric Assay kit (Cat. No. MAK089) 
were also purchased from Sigma-Aldrich Inc. 
(Brøndby, Denmark). Anti-TfRA, anti-TfRD, 
anti-TfRA/BACE1 (all human anti-mouse TfR with 
varying affinities) were obtained from Genentech, Inc. 
(CA, USA) under MTA A15783. Mal-PEG5000-NH2 
(Cat. No. MAL-PEG5000-NH2) was purchased from 
JenKem technology (Beijing, PRC). MeO-PEG5000-NH2 
(Cat. No. PEG1154) was purchased from Iris Biotech 
GmbH (Marktredwitz, Germany). Tetrachloroauric 
acid tetrahydrate (Cat. No. 077-00931) was purchased 
from Wako Chemicals GmbH (Neuss, Germany). 
LiCor IRDye® 800CW goat anti-human IgG (H + L; 
Cat. No. 926-32232) and Odessey® Blocking Buffer (in 
Tris-buffered saline, TBS; Cat. No. 927-50000) was 
purchased from Li-Cor Biosciences (Køge, DK). 
DNase I (Cat. No. 1014159001), collagenase/dispase 
(Cat. No. 109113), basic fibroblast growth factor 
(bFGF; Cat. No. 1363697), and insulin-transferrin- 
sodium selenite (Cat. No. 11074547001) were 
purchased from Roche (Hvidovre, DK). Pierce Traut’s 
reagent (2-iminothiolane; Cat. No. 26101), 
nitrocellulose blotting membranes (Pre-cut sheets, 
80×80 mm, 0.2 µm; Cat. No. LC2000) and 20X TBS 
buffer (Cat. No. 28358), rabbit anti-ZO-1 (Cat. No. 
61-7300), Alexa Fluor 594-conjugated goat anti-mouse 
IgG (Cat. No. A11032), Alexa Fluor 594-conjugated 
goat anti-rabbit IgG (Cat. No. A11034), Alexa Fluor 
488-conjugated donkey anti-rat IgG (Cat. No. 
A-21202), human IgG isotype control (Cat. No. 
02-7102), collagenase II (Cat. No. 17101105), 
Dulbecco’s Modified Eagle Medium (DMEM; Cat. No. 
21885), DMEM-F12 GlutaMAXTM (DMEM-F12; Cat. 
No. 31331), fetal calf serum (Cat. No. 10270), and 
Mouse Aβ40 ELISA kit (Cat. No. KMB3481) were 
purchased from Thermo Scientific (Hvidovre, DK). 
Bovine serum albumin (BSA; Cat. No. EQBAH62) was 
purchased at Europa Bioproducts (Cambridge, UK). 
Plasma-derived bovine serum (Cat. No. 60-00-810) 
was purchased from First Link (Wolverhampton, 
UK). Gentamicin sulphate (G418; Cat. No. 17-518Z) 
was purchased from Lonza Copenhagen (Vallensbæk 
Strand, DK). Fluorescence mounting medium (Cat. 
No. S3023) was purchased from DAKO (Glostrup, 
DK). Hanging cell culture inserts (Transwell; Cat. No. 
Pirp 15R48), rabbit anti-occludin (Cat. No. ABT146) 
and Amicon Ultra 4 mL spin filters with 30 kDa 
cut-off (Cat. No. UFC803096) were purchased from 
Merck Millipore (Hellerup, DK). Rabbit anti-CD31 
(Cat. No. ab28364) was purchased from Abcam 
(Cambridge, UK). Rat anti-mouse TfR (clone RI7217) 
was produced in-house using the hybridoma 
technique. Isoflurane was purchased from Baxter 
(Søborg, DK). Sodium cacodylate trihydrate (Cat. No. 
12300), uranyl acetate (Cat. No. 22400), and nickel 
TEM grids coated with a carbon-stabilized formvar 
film (Cat. No. FCF200-Ni) were purchased from 
Electron Microscopy Sciences (Hatfield, PA, USA). 
Agar 100 Resin (Cat. No. AGR1031) was purchased 
from Agar Scientific (Stansted, UK). Absolute ethanol 
(Cat. No. 20821.310) and acetonitrile (Cat. No. 
20066.296) were purchased from VWR International 
(Søborg, DK). Recombinant mouse TfR protein was 
purchased from SinoBiological, Inc. (Beijing, PRC). 
Instrumentation for chemical synthesis 
Reactions were monitored by thin layer 
chromatography (TLC); visualization was carried out 
by UV light exposure (254 nm), Cemol and 
KMnO4-stain. Chromatography refers to open 
column chromatography on silica gel. NMR spectra 
were recorded on a Varian Mercury 400 MHz 
Spectrometer. 1H and 13C NMR were recorded at 400 
and 100 MHz, respectively. Chemical shifts (δ) were 
reported in parts per million (ppm) relative to the 
solvent signal peak. Mass spectra were recorded on a 
Bruker AutoflexTM MALDI-TOF MS Spectrometer, 
using 2,5-dihydroxybenzoic acid (DHB) spiked with 
sodium trifluoroacetate in CH3OH as matrix. FT-IR 
was recorded neat on a PerkinElmer Instruments 
Spectra One FT-IR Spectrometer. Dynamic light 
scattering (DLS) and ζ-potential measurements were 
performed on a Brookhaven Instruments Corporation 
ZetaPALS ζ -potential analyzer. The UV-Vis 
measurements of the AuNPs were performed on a 
NanoDrop 2000c spectrophotometer (Thermo 
Scientific, Waltham, MA, USA). The amount of 
functionalized antibody per AuNP was quantified by 
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dot blotting and imaged by a Li-Cor OdesseyFC at 800 
nm with 5 min exposure time. 
Synthesis 
N-Hydroxysuccinimide-α-lipoic acid (Figure S10) 
α-Lipoic acid (4.85 mmol, 1 equiv.) and 
N-hydroxysuccinimide (5.82 mmol, 1.2 equiv.) were 
dissolved in dry tetrahydrofuran (THF; 24 mL, 0.2 M) 
in a flame-dried flask, fitted with a magnet and 
N2-atmosphere. The mixture was cooled to 0 °C. DCC 
(5.82 mmol, 1.2 equiv.) was dissolved in dry THF (4 
mL, 1.4 M) and added dropwise. The yellow reaction 
mixture was left to react and reach room temperature 
overnight. The reaction was stopped by removing the 
precipitate by filtration through Celite filter, and the 
filtrate concentrated in vacuo. The crude product was 
washed with cold ether and set to precipitate in the 
freezer before decanting. The product was used in the 
next step without further purification. 1H NMR (400 
MHz, CDCl3) δ (ppm): 3.57 (dq, J = 8.2, 6.4 Hz, 1H), 
3.21 – 3.07 (m, 2H), 2.83 (bs, 4H), 2.62 (t, J = 7.3 Hz, 
2H), 2.50 – 2.42 (m, 1H), 1.92 (dq, J = 13.5, 6.9 Hz, 1H), 
1.82 – 1.66 (m, 4H), 1.61 – 1.48 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 169.24, 168.52, 56.21, 40.28, 38.64, 
34.53, 30.91, 28.44, 25.72, 24.48. MALDI-TOF MS, m/z: 
Calc. mass [M+Na]+ = 326.0; found mass [M+H]+ = 
325.8. 
MeO-PEG5000-LA (Figure S10) 
MeO-PEG5000-NH2 (0.052 mmol, 1 equiv.) was 
dissolved in dry CH2Cl2 (5 mL, 0.01 M, dried with 4 Å 
molecular sieves) in a 10 mL flame dried flask fitted 
with a magnet and N2-atmosphere. Dry Et3N (0.36 
mmol, 7 equiv.) was added and let to react for 15 min. 
NHS-LA (0.27 mmol, 5 equiv.) was dissolved in dry 
CH2Cl2, transferred to the reaction mixture and left to 
react for 2 days. The reaction was stopped by 
concentrating in vacuo. The crude MeO-PEG-LA was 
purified by flash column chromatography (FCC; 
eluent: CHCl3:CH3OH; gradient: 1–20% over 20 
fractions; fraction volume: 20 mL). The pure fractions 
were collected and concentrated in vacuo, dissolved 
in CH3OH:MilliQ water (1:4) and lyophilized to a 
white powder (75% yield). TLC (CHCl3:CH3OH (9:1), 
KMnO4 stain). 1H NMR (CDCl3, 400 MHz), δ (ppm): 
6.29 (1H, bs, NH); 3.82-3.79 (2H, m, O-CH2-CH2-NH-); 
3.69-3.53 (m, –CH2(OCH2CH2)115–OCH3 and CH–S); 
3.48-3.43 (2H, m, NH–CH2); 3.37 (3H, s, OCH3); 
3.20-3.06 (4H, m, S–CH2–, O-CH2-CH2-NH); 2.50-2.41 
(1H, m, S–CH2–HCH–CH–S); 2.29 (2H, t, CH2– 
C(O)NH); 1.96-1.85 (1H, m, S–CH2–HCH–CH–S); 
1.79-1.60 (4H, m, CH2–CH2–CH2–CH2–C(O)–NH); 
1.53-1.41 (2H, m,–CH2–CH2–CH2–C(O)–NH). 13C- 
NMR (100 MHz, CDCl3), δ (ppm): 172.8 (-C(O)-); 71.9; 
70.8-69.9 (–CH2(OCH2CH2)115– OCH3); 59.3 (O-CH3); 
56.4 (CH); 40.3 (S–CH2–CH2–CH–S); 39.1 (NH–CH2); 
38.5 (S– CH2); 36.3 (CH2–CO); 34.7 (CH2–CH2–CH2– 
CO); 28.9 (–CH2–CH2–CH2–CO); 25.4 (CH2–CH2– 
CH2–CH2–CO). FT-IR: ν (cm−1): 2883, 2745, 2165, 1670, 
1467, 1360, 1341, 1097, 1060, 958, 841. MALDI-TOF 
MS, m/z: Calc. mass [M+Na]+ = 5217.04±nx44; found 
mass [M+H]+ = 5220.06±nx44. 
Mal-PEG5000-LA (Figure S10) 
Mal-PEG5000-NH2 (0.023 mmol, 1 equiv.) was 
dissolved in dry CHCl3 (3 mL, 38 mM, dried with 4 Å 
molecular sieves) in a 10 mL flame dried flask fitted 
with a magnet and N2-atmosphere. Dry Et3N (0.05 
mmol, 2 equiv.) was added and left to react for 15 min. 
NHS-LA (0.114 mmol, 5 equiv.) was dissolved in dry 
CH2Cl2, transferred to the reaction mixture and set to 
react for 2 days. The reaction was stopped by 
concentrating in vacuo. The crude MeO-PEG-LA was 
purified by FCC (Eluent: CHCl3:CH3OH; gradient: 
1–20% over 20 fractions; fraction volume: 20 mL). The 
pure fractions were collected and concentrated in 
vacuo, dissolved in CH3OH:MilliQ water (1:4) and 
lyophilized to a white powder (30% yield). TLC 
(CHCl3:CH3OH (9:1), KMnO4 stain). 1H NMR (400 
MHz, CDCl3) δ (ppm): 6.68 (2H, s, -CH=CH-); 6.24 
(1H, bs, NH); 3.85-3.77 (2H, m, O-CH2-CH2-NH-); 
3.50-3.70 (m and br s, –CH2(OCH2CH2)115–OCH3 and 
CH–S); 3.46-3.36 (5H, m, OCH3 and O-CH2-CH2-NH); 
3.19-3.04 (2H, m, S–CH2–); 2.51-2.42 (1H, m, 
S–CH2–HCH–CH–S); 2.18 (2H, t, CH2–C(O)NH); 
1.93-1.84 (1H, m, S–CH2–HCH–CH–S); 1.74-1.56 (m, 4 
H, CH2–CH2–CH2–CH2–C(O)–NH); 1.49-1.36 (2H, m, 
–CH2–CH2–CH2–C(O)–NH). 13C NMR (100 MHz, 
CDCl3) δ (ppm): 172.9 (-C(O)-); 170.6 (-C(O)-, 
maleimide); 134.3 (-CH=CH-); 70.8-69.8 (–CH2(OCH2 
CH2)115– OCH3); 56.5 (CH); 40.3 (S–CH2–CH2–CH–S); 
39.3 (NH–CH2); 39.3 (CH2-NH, maleimide) 38.5 (S– 
CH2); 36.4 (CH2–CO); 34.8 (CH2–CH2–CH2–CO); 34.6 
(CH2–CO, maleimide); 29.0 (–CH2–CH2–CH2–CO); 
25.5 (CH2–CH2–CH2–CH2–CO). FT-IR: ν (cm−1): 2883; 
1708; 1667; 1545; 1467; 1360; 1343; 1280; 1241; 1146; 
1097; 961; 841. MALDI-TOF MS, m/z: Calc. mass 
[M+Na]+ = 5217.04±nx44; found mass [M+H]+ = 
5220.06±nx44.  
Synthesis of AuNP seeds  
All glassware for the AuNP seed synthesis was 
cleaned with freshly made aqua regia, rinsed with 
MilliQ water and dried at 150 °C before seeding the 
AuNPs. All the AuNPs were characterized by 
ICP-MS, DLS, ζ–potential and UV-Vis spectro-
photometry. The final formulation was characterized 
by TEM and the Au concentration determined by 
ICP-MS. First seeding of AuNPs, d = 30 nm: A 
solution of HAuCl4·4H2O (0.23 mM, 1000 mL) was 
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adjusted to pH 7.0 by addition of NaOH (1 M). 
Sodium acrylate (40.9 mM, 332 mL) was added and 
the reaction flask gently swirled by hand. The reaction 
was left at room temperature without stirring for 5 
days. The combined solution was concentrated 2.6X 
by centrifugation (12,000 ×g, 10 min/cycle). Second 
seeding of AuNP, d = 40 nm: A solution of 
HAuCl4·4H2O (0.29 mM, 1871 mL) was adjusted to 
pH 7.0 by addition of NaOH (1 M). The concentrated 
acrylate stabilized AuNPs (d = 30 nm, 504 mL) were 
added followed by sodium acrylate (51.2 mM, 625 
mL). The reaction flask was gently swirled by hand 
and left at room temperature without stirring for 3 
days. The mPEG AuNPs were concentrated 60X to a 
final volume of 100 mL by centrifugation (12,000 ×g, 
10 min/cycle). The final AuNP solution was 
characterized by UV-Vis, DLS, ζ-potential (see Table 
1). ICP-MS was used to determine the Au 
concentration before PEGylation. 
Surface coating of AuNPs with polyethylene 
glycol 5000  
Previous experiments have justified the use of a 
surplus of PEG (8 PEGs/nm2) for the surface coating 
of the AuNPs [1, 6, 34, 51-56, 67, 68]. A 100 mL of 
AuNP solution was diluted 3 times with MilliQ water 
and divided into 2 portions of sterile 300 mL plastic 
vessels fitted with a magnet stir-bar (75 mL for control 
AuNP and 225 mL for the maleimide functionalized 
AuNPs). The PEG-mixtures were pre-mixed before 
adding them to the AuNP solution. The control 
AuNPs were PEGylated with MeO-PEG5000-LA (8 
PEGs/nm2, 2.9 µmol) and the Ab-functionalized 
AuNPs were PEGylated with Mal-PEG5000-LA:MeO- 
PEG5000-LA (1:99, 8 PEGs/nm2, 0.087 µmol : 8.6 µmol). 
The PEG mixtures were added to the AuNPs and 
vortexed. The reaction was left to react overnight at 
room temperature. UV-Vis, DLS and ζ-potential were 
measured to characterize the AuNPs (Table 1). A 
substantial change in morphology was observed 
between the non-PEGylated versus the PEGylated 
AuNPs. The AuNPs were subsequently washed 3 
times with sterile water and 3 times with 
sterile-filtered sodium borate buffer (0.2 M, pH 8.5) 
using centrifugation (6,500 ×g for 10 min/cycle). The 
Au concentration was determined by ICP-MS prior to 
antibody functionalization. 
Thiolation of antibodies and functionalization 
of AuNPs 
Anti-TfRA, anti-TfRD, anti-TfRA/BACE1 (all 
human anti-mouse TfR with varying affinities, kindly 
provided by Genentech, Inc., CA, USA under MTA 
A15783) and isotype IgG (human IgG, Thermo Fisher 
Scientific, Nærum, DK) antibodies were diluted in 0.2 
M sodium borate buffer (pH 8.5) to a final protein 
concentration of 2.5 mg/mL. The antibodies were 
mixed in the thiolating reagent, 2-iminothiolane 
(Traut’s reagent), in a molar ratio of 1:15 to obtain 
approximately 1 thiol group per antibody. The molar 
ratio of 2-iminothiolane was chosen based on an 
optimization of thiolation of the specific antibodies 
(Figure S2). The antibody-2-iminothiolane reagent 
mixture was reacted for 60 min at room temperature, 
and the thiolated antibodies transferred to Amicon 
Ultra 4 mL spin filters (MW cut-off: 30 kDa) with an 
additional volume of 0.2 M sodium borate buffer (pH 
8.5). The spin filters were centrifuged at 2,200 ×g for 
30 min at 4 °C, and the filtrate discarded. This 
washing step was repeated twice to clear the thiolated 
antibody solution from unreacted 2-iminothiolane. 
Finally, the rinsed, thiolated antibodies were 
immediately mixed with maleimide-functionalized 
AuNPs and allowed to conjugate.  
The maleimide preparation of AuNPs was 
divided into four fractions for isotype IgG, anti-TfRA, 
anti-TfRD, anti-TfRA/BACE1 functionalization in 50 
mL Falcon tubes, fitted a magnetic stir-bar and diluted 
with sterile sodium borate buffer (0.2 M, pH 8.5, 
C(Au) = 3.5 mM). An excess (approximately 3X molar 
excess to the added maleimide) of the individual 
thiolated antibodies were added to the respective 
AuNP fraction and allowed to react at room 
temperature overnight with light stirring. The 
reaction was stopped by washing the AuNPs with 
sterile-filtered sodium borate buffer (0.2 M, pH 8.5) 3 
times, and 3 times with sterile-filtered, isotonic 
HEPES buffer (10 mM, 150 mM NaCl, pH 7.4) using 
centrifugation (6,500 ×g for 15 min/cycle). Each 
fraction was concentrated to approx. 35 mM Au prior 
to determining the Au concentration by ICP-MS. The 
fractions were subsequently diluted with 
sterile-filtered, isotonic HEPES buffer (10 mM, 150 
mM NaCl, pH 7.4) to a particle concentration of 
3.33×1013 AuNP/mL and aliquoted. The final AuNPs 
were characterized by UV-Vis, TEM, EDS, DLS, 
ζ-potential, and dot blot. 
Determination of AuNP size by dynamic light 
scattering 
DLS measurements were performed on a 
ZetaPALS instrument (Brookhaven, Holtsville, USA) 
equipped with a 35 mV solid-state laser (659 nm). 
Samples were diluted in MilliQ water followed by 
equilibration to 25 °C before a minimum of five 
measurements was made of each sample. 
ζ-Potential measurements 
ζ-Potential measurements were performed on a 
ZetaPALS instrument (Brookhaven, Holtsville, USA) 
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equipped with a 35 mV solid-state laser (659 nm). 
Subsequently, the ζ-Potential measurements were 
made on the samples prepared for DLS. The samples 
were loaded to a pre-conditioned capillary cell and 
the ζ-potential was measured with an applied voltage 
of 4 V. Ten measurements were made per sample.  
Determination of antibody functionalization 
on AuNPs 
The degree of antibody functionalization was 
determined by dot blot. One milliliter of the final 
AuNP samples was added 4 µL of 2-mercaptoethanol 
and heated to 70 °C with 500 rpm shaking for 30 min. 
The reduced AuNPs were spun down with 7,000 ×g 
for 5 min, and the supernatant isolated. The 
supernatant (10 µL) was then spotted onto a 
nitrocellulose blotting membrane (8×8 cm, 0.2 µm, 
Thermo Scientific), dried at 37 °C for 5 min and 
blocked with blocking buffer (TBS (20X dilution in 
MilliQ water):Odessey Blocking Buffer, 1:1, 10 mL) for 
1 h. The blotting membrane was washed twice with 
MilliQ water, followed by blotting with a secondary 
antibody (LiCor IRDye® 800CW goat anti-human IgG 
(H + L)) in the blocking buffer (10 mL, 5,000X 
dilution). The blotting membrane was then washed 
with TBS (20X dilution in MilliQ water) with 0.1% 
Tween20 (10 mL, 3 × 10 min), with TBS (20X dilution 
in MilliQ water) (10 mL, 2 × 2 min) and then dried at 
37 °C in the dark. Finally, the blotting membrane was 
imaged at 800 nm with 5 min exposure time. The 
amount of Ab in the samples was then correlated to 
an isotype IgG standard curve. 
The number of AuNPs per volume (NAuNP) was 
determined by knowing the Au concentration and the 
diameter of the gold core measured by DLS. NAuNP 
was calculated by the two following equations: 
mAuNP = VAuNP × ρ(fcc) = (4/3) × π × r3 × ρ(fcc) (1) 
NAuNP = mAuNP / CAu(ICP-MS) = (4/3) × ((π × r3 × ρ(fcc)) / 
CAu(ICP-MS)) (2) 
where VAuNP is volume per AuNP, r is the radius 
of the AuNP, ρ(fcc) is the density of face-centered cubic 
(fcc) gold (19.3 g/cm3) and CAu (ICP-MS) is the 
concentration of Au determined by ICP-MS. Thus, the 
number of antibodies per AuNP was determined to be 
approximately 0, 9, 7, 9 and 8 for the mPEG, isotype 
IgG, anti-TfRA, anti-TfRD, and anti-TfRA/BACE1 
groups, respectively (Table 1). 
Inductively coupled plasma mass 
spectrometry of AuNPs 
Au concentration of the pure AuNPs was 
determined by ICP-MS by dissolving 20 µL 
concentrated AuNP sample in fresh aqua regia (380 
µL) and diluting with MilliQ water (9.60 mL) 
containing 2% HCl and an Ir-standard (0.5 PPB). The 
prepared samples were directly analyzed by iCAP Q 
ICP-MS (Thermo Scientific, Waltham, MA) together 
with an Au calibration curve. The Au-concentration 
was determined from plotting the calibration curve 
from an ICP-MS Au standard (intensity of 197Au) with 
a known concentration.  
Transmission electron microscopy 
characterization of AuNPs 
Three microliters of AuNP solution were 
deposited onto freshly glow discharged 200 mesh 
nickel TEM grids coated with a carbon-stabilized 
formvar film (Electron Microscopy Sciences, Hatfield, 
USA). The AuNPs adsorbed onto the film surface for 5 
min after which the excess solution was wicked away 
using filter paper. The grids were then washed in 
quick succession in three droplets of MilliQ water. 
Excess water was removed using filter paper and the 
grids allowed to air dry. 
TEM was performed utilizing a FEI Tecnai T20 
G2 (Thermo Fisher Scientific, Waltham, USA) 
operating at 200 kV located at the Center for Electron 
Nanoscopy at DTU. Both low and high magnification 
images, as well as energy dispersive X-ray spectra 
(EDS), were acquired for each AuNP sample. Images 
were acquired using a CCD camera equipped with 
Digital Micrograph (Gatan, Pleasanton, USA), and 
EDS spectra were acquired using a X-maxN Silicon 
Drift Detector (Oxford Instruments, Abingdon, UK). 
Image analysis was performed using Fiji analysis 
software [69]. Nanoparticle diameter was determined 
using the ‘analyze particle function’ of Fiji to obtain an 
area for each nanoparticle, making sure not to include 
nanoparticles that were overlapping in the 
measurements, and converting this value to a 
diameter assuming a spherical nanoparticle. A 
minimum of 250 nanoparticles were measured for 
each sample. 
Surface plasmon resonance analysis 
The binding affinities of the different anti-TfR 
antibodies were evaluated by surface plasmon 
resonance (SPR) analysis performed using a Biacore 
3000 instrument (Biacore, Sweden) equipped with an 
activated CM5 sensor chip. Recombinant mouse TfR 
protein (SinoBiological, Inc., Beijing, PRC) was 
purchased with a His-tag and immobilized on the 
sensor chip gold surface to densities of 58 fmol/mm2. 
Samples (human isotype IgG, anti-TfRA, anti-TfRD, 
anti-TfRA/BACE1) were injected for binding to the 
immobilized TfR protein at 5 μL/min at 25 °C in 10 
mM HEPES, 150 mM NaCl, 1.5 mM CaCl2, 1 mM 
EGTA, and 0.005% Tween 20 (pH 7.4). Antibody 
binding to the immobilized TfR protein was 
 Theranostics 2018, Vol. 8, Issue 12 
 
 
http://www.thno.org 
3430 
expressed as the response difference between the 
protein-coupled and an uncoupled, but activated, 
sensor chip. The dissociation constant (KD) values 
were calculated using the BIAevaluation 4.1 software 
using a Langmuir 1:1 binding model, using a drifting 
baseline with global fitting to the curves of the 
considered concentration range. The anti-TfR 
antibody clones RI7217 (rat anti-mouse) and OX26 
(mouse anti-rat) were also analyzed as positive and 
negative control, respectively. 
Cell culture 
Mouse BCECs were isolated from 6–10-week-old 
C57BL/6 mice according to the procedure described 
in Thomsen et al. [26]. All experiments and handling 
of animals were approved by the Danish National 
Council for Animal Welfare (License no. 
2013-15-2934-00893). The experiments were 
performed in accordance with relevant guidelines and 
regulations (EU directive 2010/63/EU and relevant 
local additions to this directive).  
 The mice were anesthetized with isoflurane 
(Baxter, Søborg, DK), and their heads submerged in 
70% ethanol before decapitation. The mouse brains 
were carefully removed from the skull, followed by 
dissection and removal of meninges and white matter 
using tweezers and filter paper. The gray matter was 
cut into small pieces using sterile scalpel blades while 
kept in ice-cold DMEM-F12 GlutaMAXTM (Thermo 
Scientific, Nærum, DK). The resulting suspension of 
gray matter was digested with collagenase II and 
DNase I in DMEM-F12 GlutaMAXTM at 37 °C for 75 
min in an Incubating Mini Shaker (VWR, Søborg, DK), 
after which the enzymes were inhibited by dilution of 
the tissue solution in additional DMEM-F12 
GlutaMAXTM. Afterwards, the solution was 
centrifuged at 1,000 ×g for 8 min. The different cell 
types were then separated by mixing and 
centrifugation in 20% bovine serum albumin (BSA) at 
1,000 ×g for 20 min, followed by digestion of the 
microvessel-containing pellet with collagenase/ 
dispase and DNase I in DMEM-F12 GlutaMAXTM at 
37 °C for 50 min. The microvessels were further 
separated from other cell types on a continuous 
Percoll gradient (33%). The microvessel fraction was 
then collected and seeded onto plastic dishes coated 
with collagen IV (0.15 mg/mL) and fibronectin (0.05 
mg/mL), where the BCECs could detach from the 
microvessels and grow on the culture dish surface. 
The primary BCECs were cultured in DMEM-F12 
GlutaMAXTM supplemented with 10% plasma- 
derived serum (First Link, Wolverhampton, UK), 
bFGF (1 ng/mL, Roche), heparin (100 µg/mL, 
Sigma-Aldrich), insulin-transferrin-sodium selenite 
(100 µg/mL, Roche), and gentamicin sulphate (10 
µg/mL, Lonza Copenhagen, Vallensbæk Strand, DK) 
in an incubator with 5% CO2 at 37 °C. Puromycin (an 
efflux transporter substrate, 4 µg/mL, Sigma-Aldrich) 
was added to the culture medium to remove pericytes 
present in the BCEC preparation. 
Mixed glial cells were isolated from the brains of 
2-day-old C57BL/6 mouse pups (following the 
procedure of Thomsen et al. [26]). The pups were 
decapitated, the brains removed from the skull, and 
subsequently resuspended in DMEM-F12 Gluta 
MAXTM using a Hypodermic 21G needle (Sterica, B. 
Braun Medical A/S, Frederiksberg, DK) followed by 
filtering through a Corning 40 µm nylon cell strainer 
(Sigma-Aldrich, Brøndby, DK). The filtered cells were 
then seeded into T75 culture flasks coated with 
poly-L-lysine (0.1 mg/mL, Sigma-Aldrich, Brøndby, 
DK), and cultured in an incubator at 5% CO2 at 37 °C. 
After 5 days of culture, the cells were shaken and 
thoroughly washed in PBS to release and remove 
some of the contaminating microglia cells. The growth 
medium was replenished, and the cells grown for 
another 14 days until confluency. The mixed glial cells 
(mostly astrocytes) were then seeded in 
poly-L-lysine-coated 12-well plates to be used for 
construction of the primary mouse in vitro co-culture 
models of the BBB. 
Construction of in vitro BBB models 
To construct in vitro co-culture models of the 
BBB, BCECs were detached from the culture dish and 
seeded onto the porous membrane of hanging cell 
culture inserts fitted for 12-well plates (Transwell, 
polyethylene terephthalate porous membrane, pore 
size: 1 µm). All culture inserts were coated with 
collagen IV and fibronectin. To increase the tightness 
of the BCECs, the hanging cell culture inserts were 
transferred to a 12-well plate containing a confluent 
layer of mixed glial cells (mostly astrocytes) in the 
bottom of each well, and treated with hydrocortisone, 
cAMP and RO-201724 at concentrations of 550 nM, 
250 μM and 17.5 μM, respectively. 
The integrity of the in vitro BBB was evaluated 
by measuring the transendothelial electrical resistance 
(TEER) using the Millicell ERS-2 Epithelial Volt-Ohm 
meter and STX01 Chopstick Electrodes (Millipore, 
Hellerup, DK). The corresponding permeability 
parameters to the TEER values of the in vitro BBB 
models were as presented in Thomsen et al. [26]. The 
TEER value of a coated insert without any cells were 
subtracted from all TEER measurements as 
normalization, and all values multiplied by the area of 
the culture insert (1.12 cm2). All data were analyzed 
using GraphPad 5.0 (GraphPad Software, Inc., CA, 
USA), and the TEER values presented as Ω cm2. 
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In vitro uptake and transcytosis studies of the 
AuNPs 
To evaluate the uptake and transcytosis potential 
of the different AuNP formulations, the primary in 
vitro models of the BBB were treated with 100 µg/mL 
AuNPs in the Transwell insert culture medium. The 
cells and AuNPs were incubated together for 5 h to 
obtain sufficient quantities of gold in the bottom 
chamber of the Transwell co-culture system for 
ICP-MS detection. All experiments were performed 
after reaching high TEER (regarded as > 130 Ω cm2 as 
suggested by Burkhart et al. [26] and Thomsen et al. 
[70]). No reduction in the TEER values were detected 
during the course of the experiment, indicating that 
the integrity of the in vitro BBB models was 
maintained (Figure 2B). After the incubation, samples 
were taken from the culture medium present in the 
Transwell culture insert (‘blood fraction’) and the 
bottom well (‘brain fraction’). The BCECs attached to 
the filter membrane of the Transwell culture insert 
were washed 3 × 5 min in 0.1 mg/mL heparin in 0.1 M 
PBS, followed by detachment of the BCECs by 
trypsinization (‘BCEC fraction’). The gold content was 
measured in the different fractions using ICP-MS (see 
below). The data was analyzed in GraphPad Prism 5.0 
(GraphPad Software, Inc., CA, USA), and results for 
gold uptake and transport were plotted as percentage 
of administrated dose (%AD) relative to samples 
taken from the Transwell culture insert immediately 
after AuNP administration. 
Immunocytochemistry 
Immunocytochemistry was performed on the 
primary in vitro models of the BBB to validate the 
expression of important markers for BBB integrity as 
well as the TfR. BCECs were grown to confluence on 
glass cover slips in the bottom of a 12-well cell culture 
plate. After reaching full confluency, the BCECs were 
washed 3 × 5 min in 0.1 M PBS (pH 7.4) and fixed in 
4% paraformaldehyde in 0.1 M PBS (pH 7.4) for 15 
min. After additional washing in 0.1 M PBS (pH 7.4, 3 
× 5 min), the BCECs were permeabilized and blocked 
in 0.1% Triton X-100 and 3% BSA in 0.1 M PBS (pH 
7.4) for 30 min. BCECs were incubated with 
antibodies against different TJ protein markers, 
including ZO-1, claudin-5, occludin, and CD31 in a 
co-staining setup with a primary antibody against the 
TfR (all primary antibodies were diluted 1:200 in 0.1% 
Triton X-100 and 3% BSA in 0.1 M PBS (pH 7.4)). 
Surface plasmon resonance with recombinant mouse 
TfR protein functionalized on the gold surface was 
used to ensure the specificity of the anti-TfR antibody 
(clone RI7217, KD = 6 nM, Figure S2). Incubation with 
primary antibodies proceeded for 60 min at room 
temperature, and was followed by washing in a 1:50 
dilution of the incubation buffer (0.1% Triton X-100 
and 3% BSA in 0.1 M PBS (pH 7.4)). After washing, 
Alexa Fluor 594-conjugated goat anti-rabbit, Alexa 
Fluor 594-conjugated goat anti-mouse, or Alexa Fluor 
488-conjugated donkey anti-rat secondary antibodies 
were administrated in a 1:200 dilution in incubation 
buffer (0.1% Triton X-100 and 3% BSA in 0.1 M PBS 
(pH 7.4) and incubated for 60 min. Lastly, the BCECs 
were washed thoroughly in 0.1 M PBS (pH 7.4)), the 
nuclei were stained with 4,6-diamino-2-phenylindole 
(DAPI), and the glass cover slips were mounted on 
glass slides with fluorescence mounting medium 
(DAKO, Glostrup, DK). Confocal microscopy was 
performed using a ZEISS LSM 800 confocal 
microscope (Carl Zeiss, Jena, DE), and images were 
taken using a Zeiss 63X magnification Plan 
Apochromat Oil DIC objective lens (NA 1.40). All 
images were processed using Fiji software [69]. 
Western blotting 
Additional validation of TfR expression in 
isolated BCECs was done by Western blot analysis. 
The BCECs were harvested using a cell scraper and 
PBS, and transferred into a tube and centrifuged at 
16,000 ×g for 5 min at 4 °C followed by discarding of 
the supernatant. One hundred microliters of lysis 
buffer (150 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 10 
mM HEPES, 1% Triton X-100, and Complete Protease 
Inhibitor) was added to the cell pellet, and the cell 
pellet was dissolved on ice for 20 min with vortexing 
every 3–5 min. After dissolving, the solution was 
centrifuged at 16,000 ×g for 10 min at 4 °C and the 
supernatant was transferred into a clean tube. The 
protein concentration was determined using the BCA 
assay kit (Sigma-Aldrich, Brøndby, DK). The samples 
were prepared by mixing with NuPAGE sample 
buffer and 0.02 M DTT before loading onto a precast 
Novex NuPAGE 4–12% Bis-Tris Gel with a total 
sample protein input of 3 µg. SeeBlueTM Plus2 
Pre-stained Protein Standard was loaded onto the gel 
for size reference, and the gel was run at 200 V for 40 
min. The gel was then transferred to a dry blot 
cassette on top of a nitrocellulose membrane, and dry 
blotting was performed for 7 min on an Invitrogen 
Novex iBlot Dry Blotting system. The membrane was 
then blocked in TBST containing 5% skim milk for 1 h 
at 4 °C before incubation overnight with a 1:1000 
dilution of primary antibodies against the mouse TfR 
(Abcam, ab84036, rabbit polyclonal) or β-actin 
(Sigma-Aldrich, A5441, mouse monoclonal) in TBST 
containing 5% skim milk. The next day, the membrane 
was washed 4 × 5 min in TBST containing 1% skim 
milk at room temperature, and a 1:2000 dilution of 
secondary antibodies (horse anti-mouse HRP-linked, 
Cell Signaling, 7076s, or goat anti-rabbit HRP-linked, 
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Cell Signaling, 7074s) in TBST containing 5% skim 
milk were applied to the membrane and allowed to 
incubate for 3 h at 4 °C. After extensive washing in 
TBST containing 1% skim milk, the membrane was 
developed using Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare Life 
Sciences, Brøndby, DK) and imaged using 
ImageQuant LAS 4000 (GE Healthcare Life Sciences, 
Brøndby, DK). 
In vivo studies and tissue isolation 
All procedures and handling of animals were 
approved by the Danish National Council for Animal 
Welfare (License no. 2013-15-2934-00893) and 
planning was made using the Experimental Design 
Assistant (National Centre for the Replacement, 
Refinement & Reduction of Animals in Research, UK). 
The experiments were all performed in accordance 
with relevant guidelines and regulations (EU directive 
2010/63/EU and relevant local additions to this 
directive). To study the uptake and trans-BBB 
transport capacity of the different TfR-targeted AuNP 
formulations plus controls in vivo, the AuNPs were 
injected via the lateral tail vein into 8-week-old female 
Balb/c mice (n = 8 per group) and allowed to circulate 
for 8 h [23]. The administrated dose of the individual 
AuNP formulations (mPEG, isotype IgG, anti-TfRA, 
anti-TfRD, or anti-TfRA/BACE1) was 5×1011 AuNPs/ 
mouse as previously described in Wiley et al. 
(2013)[23].  
After systemic circulation for 8 h, the mice were 
deeply anesthetized by a subcutaneous injection of 0.5 
mL/10 g body weight of Hypnorm/Dormicum 
(fentanyl/fluanisone mixed with midazolam and 
sterile water in a ratio of 1:1:2). The chest cage of the 
mouse was opened, and the heart was exposed for 
transcardial perfusion of 0.1 M PBS (pH 7.4). After 
perfusion, the skull was opened, and the brain 
removed for subsequent brain capillary depletion 
(one hemisphere, see below) or sampling for 
biodistribution analysis (one hemisphere). 
Furthermore, tissue samples were taken from the 
liver, spleen, kidney, heart, and lungs were resected 
for biodistribution analysis as well. All biodistribution 
tissue samples were quickly frozen on dry ice and 
stored until further processing for ICP-MS 
quantification of the gold content. 
Before perfusion of the animals, a blood sample 
was drawn from the left ventricle of the heart into a 
tube containing heparin. All blood samples were 
centrifuged at 2,000 ×g for 15 min to pellet cells and 
platelets contained in the sample, and the resulting 
plasma was transferred into a clean tube and stored 
until further processing for ICP-MS. The gold content 
in all blood and tissue samples were measured using 
ICP-MS (see below) and the resulting data plotted as 
%ID/g in GraphPad Prism 5.0 (GraphPad Software, 
Inc., CA, USA). 
A subset of mice (n = 4 per group) was dedicated 
to morphological analyses using either light 
microscopy or TEM. After circulation of the AuNPs, 
the mice were deeply anesthetized by a subcutaneous 
injection of 0.5 mL/10 g body weight of 
Hypnorm/Dormicum (fentanyl/fluanisone mixed 
with midazolam and sterile water in a ratio of 1:1:2). 
Once full anaesthesia was reached, the chest cage was 
opened, and the mice were transcardially perfused 
with 0.1 M PBS (pH 7.4). Afterwards, the mice were 
re-perfused with either 4% paraformaldehyde in 0.1 
M PBS (pH 7.4) for subsequent cryosectioning and 
light microscopy, or 4% paraformaldehyde, 2% 
glutaraldehyde in 0.1 M sodium cacodylate buffer 
(pH 7.4) for subsequent processing for TEM. The 
brains dedicated to light microscopy were transferred 
into a vial containing 4% paraformaldehyde in 0.1 M 
PBS (pH 7.4) to continue the fixation process 
overnight. After fixation, the brains were moved to a 
30% sucrose solution and allowed to settle, before 
they were cryosectioned into 40 µm thick slices and 
stored at –20 °C in antifreeze solution until further 
processing. The brains dedicated to TEM were 
transferred into a vial containing 4% 
paraformaldehyde, 2% glutaraldehyde in 0.1 M 
sodium cacodylate buffer and allowed to fixate until 
further processing for TEM (see below). 
Another subset of mice (n = 4 per group, only 
groups isotype IgG, anti-TfRA/BACE1, and untreated 
control) received a dose of 1×1012 AuNPs/mouse 
(corresponding to a doubling of the dose used for 
quantitative studies), which circulated for 30 h before 
termination. The mice were then anesthetized and 
perfused with 0.1 M PBS (pH 7.4) as described above, 
before their skulls were opened and their brains 
removed. The brains were quickly frozen on dry ice 
and stored at –80 °C before processing for subsequent 
ELISA-based quantification of their β-amyloid protein 
load (see below). 
Brain capillary depletion 
To indicate the presence of AuNPs in the brain 
parenchyma, the brain capillary depletion technique 
was employed to separate the brain capillaries from 
the rest of the brain cells according to the protocol by 
Triguero et al. with minor modifications [46, 59]. One 
brain hemisphere was sampled from each mouse and 
homogenized by four strokes in a dounce 
homogenizer containing ice-cold homogenization 
buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 
mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, and 10 mM 
glucose; pH 7.4), followed by addition of ice-cold 30% 
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dextran (MW: 60,000, Sigma-Aldrich) and further 
homogenization by four strokes in the dounce 
homogenizer. The brain homogenate was transferred 
into a 15 mL Falcon tube, and subsequently 
centrifuged at 3,500 ×g for 40 min at 4 °C with slow 
deceleration. After centrifugation, the brain homo-
genate had separated into a brain capillary-containing 
pellet, and a supernatant containing the brain 
parenchymal fraction. Samples were taken from both 
the capillary and parenchymal fractions, and the gold 
content was measured by ICP-MS (see below).  
Measurement of γ-glutamyl transferase 
activity 
The purity of the depleted brain capillaries and 
parenchyma was analyzed by measuring the activity 
of γ-glutamyl transferase in the sampled fractions 
using the γ-Glutamyl Transferase (GGT) Activity 
Colorimetric Assay kit (Sigma-Aldrich, Brøndby, DK) 
according to the manufacturer’s protocol. Briefly, 
sample volumes corresponding to a total of 10 mg 
tissue were taken from each fraction and 
homogenized in ice-cold GGT Assay buffer. The 
homogenized tissue samples were then centrifuged at 
13,000 ×g for 10 min at 4 °C to pellet any insoluble 
material. Ten microliters of the supernatant were 
transferred into a flat-bottom 96-well plate together 
with positive controls and standard curve samples. 
Additional 90 µL GGT Substrate Solution were added 
to each well (except for the standard curve samples), 
and the mixture was allowed to incubate for 3 min at 
37 °C before taking an initial measurement of the 
absorbance at 418 nm using an EnSpire Multimode 
Plate Reader (Perkin-Elmer, Waltham, MA, USA). The 
samples continued to incubate at 37 °C and the 
absorbance at 418 nm was measured every 5 min to 
follow the conversion process. The initial and final 
absorbance measurements were used for calculating 
the enzyme activity presented as nmol/min/mL. 
Inductively-coupled plasma mass 
spectrometry of tissue and cell samples 
Inductively-coupled plasma mass spectrometry 
(ICP-MS) was used to analyze the gold content of the 
extracted tissue samples. A maximum of 100 mg 
tissue per sample were digested in aqua regia 
overnight at 65 °C, and after digestion, the samples 
were diluted in pure MilliQ water containing 0.5 ppb 
iridium (Fluka, Sigma-Aldrich, Brøndby, DK). Just 
prior to ICP-MS analysis, the samples were further 
diluted in 2% HCl containing 0.5 ppb iridium, and the 
samples were analyzed on a iCAP Q ICP-MS system 
(Thermo Scientific, Hvidovre, DK) fitted with an 
ASX-520 AutoSampler and a Neclar ThermoFlex 2500 
chiller. The system was calibrated using TUNE B 
iCAP Q element mixture (Thermo Scientific, 
Hvidovre, DK) prior to analysis. To obtain the gold 
concentration of the samples, a standard curve was 
generated based on serial dilution of an analytical 
standard gold solution (Fluka, Sigma-Aldrich, 
Brøndby, DK) to obtain data points ranging from 
0.08–5 ppb. The iridium concentration was also 
measured during the analysis as an internal standard, 
showing that all samples were analyzed similarly. The 
resulting data was plotted as %ID/g in GraphPad 
Prism 5.0 (GraphPad Software, Inc., CA, USA). 
Transmission electron microscopy of AuNPs 
in brain tissue 
The cortices from the tissue set aside for TEM 
analysis were carefully excised from the remaining 
brain tissue and cut into 1 mm3 pieces for further 
processing. The tissue pieces were washed 2 × 10 min 
in 0.1 M Na cacodylate buffer to remove residual 
fixative and suspended in 1% OsO4 in 0.1 M sodium 
cacodylate buffer for 1 h at 4 °C. The samples were 
then washed twice in MilliQ water followed by 
resuspension in 1% uranyl acetate in water overnight. 
The next day, the samples were washed twice in 
MilliQ water and re-suspended in increasing 
concentrations of ethanol; 50%, 70%, 95%, 100% and 
100% for 15 min each. The samples were then washed 
3 × 5 min in acetonitrile and infiltrated with a 1:1 
solution of Agar 100 resin:acetonitrile for 1 hour (Agar 
100 resin is a replacement resin for Epon 812). Next, 
the samples were infiltrated with a 2:1 solution of 
Agar 100 resin:acetonitrile overnight. The following 
day, the samples were infiltrated with pure Agar 100 
resin for 1 h. The tissue pieces were then placed in 
BEEM capsules (Agar Scientific, Stansted, UK) and 
covered with resin. Then, the samples were placed in 
a curing oven at 60 °C overnight to polymerize. After 
polymerization, the samples were removed from the 
BEEM capsules, trimmed using a razor blade and thin 
sections (200 nm thick) were cut using a RMC MT-7 
Ultramicrotome (Boeckeler Instruments, Tucson, 
USA) equipped with a glass knife. These thin sections 
were then placed on 200 mesh nickel TEM grids 
coated with a carbon stabilized formvar film (Electron 
Microscopy Sciences, Hatfield, USA) with a hole 
length of 95 µm. 
TEM was performed utilizing a FEI Tecnai T20 
G2 (Thermo Fisher Scientific, Waltham, USA) 
operating at 200 kV located at the Center for Electron 
Nanoscopy at DTU. Images were acquired using a 
CCD camera equipped with Digital Micrograph 
(Gatan, Pleasanton, USA) and EDS spectra were 
acquired using a X-maxN Silicon Drift Detector 
(Oxford Instruments, Abingdon, UK). Brain tissue 
was imaged in a systematic manner by scanning 
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entire grid sections at low magnification, 2500x. The 
contrast was optimized by condensing the beam such 
that the top left corner of the CCD camera was not 
illuminated. This allowed for straight forward 
identification of AuNPs versus salt crystals and other 
sample preparation artifacts. Once AuNPs were 
identified higher magnification images were acquired, 
and for AuNPs located within the brain parenchyma, 
EDS spectra were acquired. Processing and TEM 
imaging of liver and spleen tissues were performed 
using the same methodology. 
Quantification of brain β-amyloid protein load 
To study the potential therapeutic efficacy of the 
anti-TfRA/BACE1 antibody after AuNP transport into 
the brain, the brain β-amyloid protein load was 
measured using enzyme-linked immunosorbent assay 
(ELISA)[16]. Approximately 100 mg brain tissue was 
weighed and homogenized in 5 M guanidine-HCl/50 
mM Tris. The mixture was incubated at room 
temperature for four hours under constant shaking. 
After incubation, the mixture was diluted in cold 
BSAT-PBS containing 1X protease inhibitor cocktail to 
reduce the guanidine concentration to less than 0.1 M. 
The diluted samples were then centrifuged at 16,000 
×g for 20 min at 4 °C, and the supernatant was 
transferred to a clean tube and stored at –80 °C until 
β-amyloid quantification by ELISA. 
 The β-amyloid load was measured using the 
Mouse Aβ40 ELISA kit (Thermo Fisher Scientific, 
Naerum, DK) according to manufacturer’s protocol. 
Briefly, the mouse brain protein samples were 
administrated to individual wells in a 96-well plate 
containing surface-bound capture antibodies against 
mouse Aβ40 and incubated for two hours. A detection 
antibody solution was then applied and incubated for 
another hour, followed by incubation with 
HRP-labelled secondary antibody solution for 30 min. 
After washing, stabilized chromogen solution (HRP 
substrate) was administrated and incubated for 30 
min to induce a color change correlating with the 
Aβ40 concentration. Lastly, a stop solution was 
applied to halt the reaction, and the absorbance at 450 
nm was read immediately on an EnSpire Multimode 
Plate Reader (Perkin-Elmer, Waltham, MA, USA). 
Silver enhancement on brain tissue sections 
Silver enhancement was performed on fixed 
brain tissue sections to develop the AuNPs to a size 
adequate for the resolution of the light microscope 
[22, 23, 60]. The silver enhancement was made using 
the Silver Enhancement Kit (Sigma-Aldrich, Brøndby, 
DK) according to the manufacturer’s instructions. 
Brain cryosections (40 µm) from animals treated with 
the different AuNP formulations were thoroughly 
washed in KPBS three times before fixation in 2.5% 
glutaraldehyde for 15 min at room temperature. After 
fixation, the brain sections were rinsed three times in 
MilliQ water to remove traces of buffer salts etc., 
followed by removal of excess fluid before the silver 
enhancement process. The Silver Enhancer Mixture 
was applied to the brain sections and allowed to react 
for 15 min before rinsing in MilliQ water. Finally, the 
brain sections were fixed in 2.5% sodium thiosulfate 
for 3 min before additional washing with MilliQ 
water. Counterstaining with hematoxylin was 
performed for 5 min with thorough rinsing in tap 
(lukewarm) and MilliQ water afterwards. The 
mounted brain sections were then dried, covered in 
mounting medium and protected by glass coverslips. 
Liver sections were treated as explained above and 
served as a positive control for the specific 
development of AuNP size. Images were acquired on 
an Axioplan 2 Imaging Microscope (Carl Zeiss, Jena, 
DE) using a Zeiss 100X magnification Plan Neofluar 
Oil objective lens (NA 1.30), and brightness and 
contrast were adjusted using Fiji software [69]. 
Statistical analysis 
All data were analysed in GraphPad Prism 5.0 
(GraphPad Software, Inc., CA, USA) and presented as 
the arithmetic mean ± standard error of the mean 
(SEM). The statistical significances of intergroup 
differences were calculated using the parametric 
unpaired T-test or one-way ANOVA with Tukey’s 
multiple comparisons post hoc test for normally 
distributed data/data with equal variances, or the 
non-parametric Mann-Whitney’s U Test or 
Kruskal-Wallis test with Dunn’s multiple compar-
isons post hoc test for non-normally distributed 
data/data with unequal variances. Potential outliers 
in a dataset were tested using Grubbs’ test in 
GraphPad QuickCalcs (GraphPad Software, Inc., CA, 
USA). A p-value < 0.05 was considered statistically 
significant. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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